Objective To analyze the use of new antitumor drugs in Tianjin Baodi Hospital from January 2020 to June 2024,and analyze their use trend,so as to provide reference for the scientific management and clinical rational drug use of new antitumor drugs in the hospital.Methods Using the analysis method of defined daily dose(DDD)recommended by the World Health Organization(WHO),the medication frequency(DDDs)and average daily cost(DDC)of each hepatoprotective drugs were calculated,and the sales amount and DDDs of drugs were ranked,respectively,and the ranking ratio was calculated.Results From January 2020 to June 2024,Tianjin Baodi District People's Hospital has a total of 30 types of new anti-tumor drugs,including 15 small-molecule targeted drugs and 15 large-molecule monoclonal antibody drugs.The sales sum and frequency of use are mainly large-molecule monoclonal antibody novel anti-tumor drugs,accounting for more than 90%.Among them,the use of carrilizumab had the best synchronization,and except for rituximab 2022,the DDC of other drugs showed a downward trend.Conclusion The use of new antitumor drugs in Tianjin Baodi Hospital is basically reasonable.
new anti-tumor drugsDDDsales amountDDDsDDCaverage annual growth ratecarrilizumabrituximab
NETL
NSTL
万方数据
